Progressive hepatic fibrosis and cirrhosis leading to end-stage liver disease are major consequences of chronic alcohol abuse that cost thousands of lives, and hundreds of millions of dollars in health care costs. Despite the clear link between alcohol, fibrosis and end-stage liver disease, there are no approved antifibrotic therapies that can delay disease progression or forestall complications of fibrosis, and thus progress is urgently needed. The hepatic stellate cell (HSC), following activation during alcoholic liver injury, plays a central role in the development of fibrosis. Our long-term goal is to understand how HSC activation is stimulated in response to alcohol;progress will lead to novel, targeted interventions for alcoholic liver disease. A study published by others describing loss of lipid droplets as a feature of autophagy sparked our idea that autophagy is a component of HSC activation. Autophagy is a highly regulated cellular response that has evolved to maintain energy homeostasis during cellular stress or enhanced metabolic demand, and its features remarkably parallel those of HSC activation. The objective of this project, which is the next step towards our long-term goal, is to characterize the contribution of autophagy to HSC activation in alcoholic liver injury. Our central hypothesis, therefore, is that autophagy is a critical and necessary component of HSC activation in alcoholic fibrosis. We will test our central hypothesis through the following interrelated Specific Aims: 1. Define stimuli associated with alcoholic liver injury that provoke autophagy in HSCs, by using ethanol-specific culture models of HSC activation in which autophagy will be documented by: Western blot to detect conversion of LC3-I protein to LC3-II, ultrastructure, and reduced lipid content. 2. Determine which features of autophagy during HSC activation in vivo are alcohol-dependent by characterizing the response to siRNA knockdown of Atg7 or Atg5 in HSCs from ethanol-fed mice, and define autophagy-regulated pathways by quantitative PCR and Western for known activation markers, and exon arrays for novel targets. 3. Establish the dependence of alcohol-related HSC activation on autophagy in vivo by blocking autophagy in alcohol-fed mice. These studies should uncover fundamental new pathways of stellate cell activation specifically related to alcohol's effects in the liver, leading to innovative treatment approaches for patients with alcoholic liver disease.

Public Health Relevance

Chronic alcoholic liver disease leads to scarring, or fibrosis, of the liver, and is a large public health challenge, affecting millions of patients. We propose to study a specialized pathway called autophagy, that drives activation of hepatic stellate cells in liver to make scar in alcoholic fibrosis. New insights expected to emerge from these novel studies could significantly advance our understanding of how to block scar formation in alcoholic liver disease, accelerate liver repair, and prevent the end-stage of liver disease called cirrhosis, thereby improving the lives of patients throughout the world.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
5R01AA020709-02
Application #
8308354
Study Section
Special Emphasis Panel (ZAA1-JJ (01))
Program Officer
Radaeva, Svetlana
Project Start
2011-08-01
Project End
2016-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
2
Fiscal Year
2012
Total Cost
$349,162
Indirect Cost
$124,162
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Martin, Katherine; Pritchett, James; Llewellyn, Jessica et al. (2016) PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat Commun 7:12502
Borkham-Kamphorst, Erawan; Steffen, Bettina T; Van de Leur, Eddy et al. (2016) CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. Cell Signal 28:34-42
Yoon, Young Joon; Friedman, Scott L; Lee, Youngmin A (2016) Antifibrotic Therapies: Where Are We Now? Semin Liver Dis 36:87-98
Dyvorne, Hadrien A; Jajamovich, Guido H; Bane, Octavia et al. (2016) Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. Liver Int 36:659-66
Aylon, Yael; Gershoni, Anat; Rotkopf, Ron et al. (2016) The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes Dev 30:786-97
Zhang, David Y; Goossens, Nicolas; Guo, Jinsheng et al. (2016) A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut 65:1754-64
Kocabayoglu, Peri; Lade, Abigale; Lee, Youngmin A et al. (2015) β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. J Hepatol 63:141-7
Torok, Natalie J; Dranoff, Jonathan A; Schuppan, Detlef et al. (2015) Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 62:627-34
Wallace, M C; Hamesch, K; Lunova, M et al. (2015) Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Lab Anim 49:21-9
Trautwein, Christian; Friedman, Scott L; Schuppan, Detlef et al. (2015) Hepatic fibrosis: Concept to treatment. J Hepatol 62:S15-24

Showing the most recent 10 out of 42 publications